Kornimate/medical-research-clean huggingface dataset:
delayed vasospasm after aneurysm with the standardization treatment of traditional chinese medicine

Conditions: Aneurysm

Summary: delayed vasospasm (dcvs) is the most serious complication of aneurysmal subarachnoid hemorrhage (asah) perioperative period ,the incidence rate up to 30% to 90%, and often can cause severe brain ischemia or brain damage of delayed ischemic and even lead to cerebral infarction, to be the main factor of deadly and severe disability . (asah) perioperative delayed vasospasm (cvs) is the bottleneck to restrict the long-term effect. since there is no standard clinical treatment programs, limiting the advantages and characteristics of traditional chinese medicine to play.guangdong provincial hospital of tcm is the province's medical center encephalopathy, treated 100 brain aneurysm patients each year, more than 80 times craniotomies and surgical interventions , with a rich source of patiengs to carry out the study. in this study, on the basis studies on hemorrhagic stroke of a yin and yang syndrome and comprehensive treatment programe of the state 1995,the 15th research , in accordance with characteristics of the pathophysiology and understanding of cause and pathogenesis in asah perioperative period , through expert advice and review of the literature, under the guidance of liu maocai who ischinese medicine practitioners of guangdong province , from diagnosis, diagnosis and treatment,prescription drugs, and other aspects of efficacy evaluation, developmenting a standardized treatment program of delayed cvs after asah . to evaluate the efficacy of the standardized program by prospective, randomized,controlled clinical trial,improving the postoperative results, reducting significantly the mortality and morbidity patients with cerebral aneurysms.


Eligibility criteria:
inclusion criteria: * between the ages of 14-80 years old patients; * comply with the diagnostic criteria for chinese and western medicine; * comply with embolization of intracranial aneurysms or cranial aneurysm surgery indications; * preoperative hunt and hess grade of ⅰ \~ ⅳ; the first disease or previous history of stroke but no sequelae; * acceptance within 72h onset cranial aneurysm embolization or craniotomy aneurysm surgeon; * informed consent; exclusion criteria: * the age of 14 years of age or in patients over 80 years of age; * by hypertension, a variety of blood diseases, amyloid angiopathy, cerebral arteritis, cerebral abnormal vascular network (moyamoya disease), brain tumor brain metastases as a result of bleeding; * associated with cardiovascular, liver and kidney and hematopoietic system of primary disease, mental illness; * 72h of onset did not receive cranial aneurysm embolization or craniotomy for aneurysm surgery were;

Keywords: delayed vasospasm, medicine, standardization
safety and efficacy study of brimonidine in patients with glaucoma or ocular hypertension

Conditions: Glaucoma; Ocular Hypertension

Summary: this study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension


Eligibility criteria:
inclusion criteria: * ocular hypertension or glaucoma in both eyes exclusion criteria: * uncontrolled systemic disease * known allergy or sensitivity to brimonidine
trial of a water beverage intervention for promoting modest weight reduction in free living adults

Conditions: Obesity

Summary: the primary objectives of this clinical trial are to determine if replacing sugar sweetened beverages with water consumption promote weight loss over 6 months in overweight adults and if replacing sugar sweetened beverages with water consumption promote greater weight loss over 6 months relative to replacement with other non-caloric sweetened beverages or control. the secondary objective is to identify mediators and moderators of the effect of water replacement including hydration status, glucose metabolism, anthropometrics, physical activity, dietary intake and resting metabolic rate.


Eligibility criteria:
inclusion criteria: * 18-65 years of age. * body mass index (bmi) between 25.0-49.9 kg/m2. * subject consumes at least 280 calories per day from caloric beverages. exclusion criteria: * report losing \>5% of current body weight in the previous 6 months. * report participating in a research project involving weight loss or physical activity in the previous 6 months, as these proximal experiences may impact the results of this study. additionally, report current participating in any other research studies whose results could be compromised by or in which participation could compromise this research study. (participation in a research study that would not affect or be affected by this study is allowed.) * report pregnancy or lactation during the previous 6 months, or planned pregnancy in the next 6 months. * report taking medication that could affect metabolism or change body weight (e.g., synthroid). * report hospitalization for psychiatric problems during the prior year. * report major psychiatric diagnoses and organic brain syndromes. * report heart problems, chest pain, cancer within the last 5 years * being treated by a therapist for psychological issues or problems with psychotropic medications. * report behaviors that indicate probable alcohol dependence as assessed by the rapid alcohol problems screen (raps4-qf) (cherpitel cj, 2002). * unwilling to change intake of beverages during the study period. * plan to move from the area during the study period, and/or unable to attend monthly group meetings. * report not having adequate transportation to the study center that would allow transport of study supplies back to the subject's home. * report not being able to attend group meetings on monday or tuesday evenings.
test retest reliability of oa and oh

Conditions: Analgesia; Pain Catastrophizing; Pain

Summary: the goal of this study is to measure the test retest reliability of offset analgesia (oa) and onset hyperalgesia (oh) across multiple study visits. oa and oh are quantitative sensory tests (qst) thought to measure how the brain modulates pain. this study will use a heat thermode to induce oa and oh in healthy, pain-free volunteers across 3 study visits. additional qst measures and survey data relevant to pain modulation will be collected. this study lays the foundation required to use oa and oh as tools to measure pain modulation in clinical trials. following their validation, we anticipate that oa and oh will serve as predictive and therapeutic biomarkers, which will aid both in the development of novel analgesics and in treatment selection leading to the personalization of pain management.


Eligibility criteria:
inclusion criteria: * healthy volunteers with no chronic pain issues who can understand the study procedures exclusion criteria: * history of chronic pain * current significant pain disorder * active ongoing pain every day that is acute or chronic in duration * recent history of migraine (1 attack in last 24 months) * lifetime history mood disorders (anxiety, depression, bipolar) or psychotic disorders. * subjects taking psychotropics (e.g. benzodiazepines, antidepressants), or medications known to affect the autonomic nervous system (e.g. beta-receptor agonists or antagonists) will be excluded. * cognitive impairment affecting the ability to provide informed consent, understand directions, and participate in study procedures * uncontrolled or unstable medical disorder preventing participation in study procedures * pregnancy * tattoos on forearm * history of brain surgery * nonambulatory status * heart problems such as an irregular heart beat or coronary artery disease * neurological problems such as seizure, fainting spells, recurrent severe headache, stroke, transient ischemic attack * high blood pressure * severe liver disease * severe gastrointestinal disease * chronic severe infectious disease (e.g. hiv/aids)
the efficacy of botulinum toxin in spastic neuropathic bladder

Conditions: Spastic Neurogenic Bladder

Summary: to assess the efficacy of botulinum toxin in spastic neurogenic bladder.

neurogenic detrusor overactivity (ndo) can result in lower and upper urinary tract complications and eventually even in end-stage kidney failure. since the driving force of this clinical cascade is high bladder pressure, controlling intravesical pressure in ndo patients improves both quality of life and life-expectancy in these patients. botulinum toxin a (btx-a) has proven its efficacy in reducing intravesical pressure and in reducing incontinence episodes. btx-a also improves quality of life in patients with ndo. both onabotulinumtoxina (botox®, allergan, irvine, usa) and abobotulinumtoxina (dysport®, ipsen, paris, france) have a level a recommendation for ndo-treatment. the recommended dose for intradetrusor injections in ndo patients is 200 u of onabotulinumtoxina or 500 u of abobotulinumtoxina. the drug is generally administered extratrigonal in the detrusor muscle, via cystoscopic guided injection at 20 sites in 1 ml injections. intradetrusor btx-a injections are safe, with mostly local complications such as urinary tract infection and high post-void residual or retention. the effect of the toxin lasts for approximately 9 months. repeat injections can be performed without loss of efficacy. different injection techniques, novel ways of btx-a administration, eliminating the need for injection or new btx-a types with better/longer response rates could change the field in the future. botulinum toxins are neurotoxins produced by the facultative anaerobe clostridium botulinum that block the release of acetylcholine into the synaptic gap of the neuromuscular junction. their injection near the nerves that supply the target organ selectively and temporarily paralyzes the organ. in particular, the subtype botulinum-a toxin is widely used in neurology to release spastic dystonia in adults and children . in urologic disorders, botulinum-a toxin reliably diminishes external sphincter or detrusor overactivity.

Eligibility criteria:
inclusion criteria: -1- patients with spastic neurogenic bladder due to upper motor neuron lesion as (spinal cord lesions ,multiple sclerosis ,strokes,parkinsonism...........). 2- patients with spastic neurogenic bladder diagnosed clinically and urodynamically. exclusion criteria: * 1-patients with associated lower motor neuron lesions. 2-atonic bladder. 3-patients with diabetes mellitus.
icotinib combined with wbrt for nsclc patients with brain metastases and egfr mutation

Conditions: Non-small Cell Lung Cancer; Brain Metastases

Summary: the purpose of this study is to evaluate the safety and tolerability of icotinib at different dose levels in combination with whole brain radiotherapy for nsclc patients with brain metastases and egfr mutation.

the long-term control of brain metastases becomes a clinical challenge. whole brain radiotherapy, the standard treatment for patients with multiple brain metastases, can only bring a modest survival improvement around 3-6 months. egfr-tkis like icotinib with its proven activity in non-small cell lung cancer may provide clinical benefits in such patients.

Eligibility criteria:
inclusion criteria: * histological or cytological confirmation of non-small cell lung cancer (nsclc). * diagnosis of brain metastases on a gadolinium-enhanced mri. more than 3 sites of intracranial metastases, or the longest diameter of the intracranial lesion is more than 3cm. * positive egfr mutation. exclusion criteria: * previous usage of egfr-tki or antibody to egfr: gefitinib, erlotinib, herceptin, erbitux. * csf or mri findings consistent with metastases of spinal cord, meninges or meningeal.

Keywords: safety egfr-tki nsclc icotinib wbrt
embocube gelatin embolization to control bleeding or hemorrhaging

Conditions: Hemorrhage; Bleeding Hemorrhage

Summary: this is a multicenter, observational study of the use of embocube embolization gelatin to control hemorrhaging and bleeding. the study is designed to enable the collection, analysis, and reporting of data from "real-world" use of embocube used in accordance with the instructions for use (ifu) associated with the product's ce mark approval. data collection will include that relating to safety and effectiveness and the period of observation during which data will be collected will extend from the index procedure through 28 days post procedure.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. subject requires embolization and is suitable for treatment with embocube in accordance with device instructions for use for the treatment of bleeding or hemorrhage. 3. subject provides written informed consent to study data collection. exclusion criteria: 1. bleeding site in the neck, head, or brain. 2. subject has co-morbidity with survival prognosis of less than 30 days, in the opinion of the treating physician 3. in the investigator's opinion, participation in the study may not be in the subject's best interest.
tdcs and spasticity in stroke patients

Conditions: Stroke

Summary: multiple research has worked on tdcs and its impact on stroke. but none have studied the effects of tdcs on stroke in relation to the different stages of stroke like mild, moderate, moderate to severe and severe stroke as per national institute of health (nih) scale. additionally, this study will be conducted to address the few drawbacks in previous studies such as short follow up period by employing evidence based standardized protocols. it can potentially instigate the efficacy of tdcs on spasticity, motor recovery and quality of life in relation to the different severity levels of stroke.

multiple noninvasive brain stimulation is also introduced over the few years regarding their impact on spasticity, tdcs being the most common due to its effects on spasticity. there are multiple structural and functional changes in motor cortex post stroke, tdcs causes improvement in motor control by reorganizing the motor cortex. anodal and cathodal tdcs are based on the current direction with cathodal decreasing excitability of the cortex area and anodal increasing it. anodal tdcs is more effective in reducing spasticity as compared to cathodal. the change in cortical excitation alters the reflex arc i.e. altering the neurons and reducing their excitability which causes a decrease in tone and facilitates neuroplasticity. spasticity is often found along with weakness in stroke and is one of the reasons for impaired motor function, increased resistance to stretch and is due to increased excitability and abnormal regulation of spindle and reflex arc. with chronicity and reduced motor control spasticity also increases by 97 %. spasticity and paresis lead to impaired motor control. spasticity will not change recovery in function in early stages but is going to affect motor recovery in all stages. spasticity disrupts motor function and the daily tasks which creates different levels of dependence in the patients hence effecting the qol. spasticity is found in almost 40% of individuals suffering from stroke. it affects joints and extremities in a way that impedes function and adls. painful, restricted joints resulting from prolonged spasticity badly impacts the qol leading to high burden on caregivers

Eligibility criteria:
inclusion criteria: * stroke for more than 6 months. * both genders. * spasticity score ≥1 at modified ashworth scale. * national institutes of health stroke scale (nihss) for severity level; mild (1-4), moderate (5-15), moderate to severe (16-20), severe (21-42) exclusion criteria: * have any metallic implant including intracranial electrode, pacemaker, surgical clip. * any symptoms effecting understanding of instructions. * any neurological disorder

Keywords: stroke spasticity transcranial direct current stimulation
optical biopsy for peritoneal nodules in colorectal patients

Conditions: Colorectal Cancer

Summary: during surgery, peritoneal metastasis is typically confirmed pathologically through resection sample. however, this process can be time-consuming when utilizing intro-operative frozen section pathology. to address this issue, we propose utilizing confocal laser endomicroscopy to provide in situ, real-time, and in-vivo diagnosis of suspected peritoneal nodules as cancer metastasis during surgery.

peritoneal metastasis is a common metastatic site in colorectal cancer patients, and those with peritoneal metastasis often have a poor prognosis. during surgery, peritoneal metastasis is confirmed pathologically through resection sample, but frozen section pathology can take up to 30 minutes, which is a significant amount of time. to address this issue, we suggest utilizing probed-based confocal laser endoscopy (pcle), a novel endoscopic adjunct that enables real-time in vivo histological examination of mucosal surfaces. by using intravenous fluorescent agents, pcle highlights certain mucosal elements that facilitate an optical biopsy in real time. by providing a promising optical biopsy, cle has the potential to enable in situ, real-time, and in vivo diagnosis of colorectal cancer patients with peritoneal nodules during surgery.

Eligibility criteria:
inclusion criteria: 1. age from over 18 to under 85 years 2. american society of anesthesiology (asa) score class i,ii,or iii 3. colorectal cancer 4. patients who be about to undergo surgical treatment 5. written informed consent exclusion criteria: 1. pregnant or lactating women 2. acute renal insufficiency or stage ii to iv chronic renal insufficiency 3. patients with severe liver damage 4. asthma patients or patients with allergic constitution

Keywords: colorectal cancer confocal laser endomicroscopy optical biopsy
risk stratification for venous thromboembolism in hospitalized medical patients

Conditions: Venous Thromboembolism; Venous Thromboses; Pulmonary Embolism; Deep Vein Thrombosis; Embolism and Thrombosis; Mobility Limitation; Hospital Acquired Condition

Summary: hospital-acquired venous thromboembolism (ha-vte) is one of the leading preventable causes of in-hospital mortality, but prevention of vte in hospitalized medical patients remains challenging, as preventive measures such as pharmacological thromboprophylaxis (tpx) need to be tailored to individual thrombotic risk. the broad objective of this project is to improve vte prevention strategies in hospitalized medical patients by prospectively examining vte risk factors (including mobility) and comparing existing risk assessment models.


Eligibility criteria:
inclusion criteria: * age ≥18 years * admitted for hospitalization \>24 hours on a general internal medicine ward * informed consent as documented by signature exclusion criteria: * need for therapeutic anticoagulation (e.g., atrial fibrillation) * life expectancy \<30 days * insufficient proficiency of the german or french language * unwilling to provide informed consent * prior enrolment in the study

Keywords: venous thromboembolism pulmonary embolism deep vein thrombosis risk factor hospital-acquired mobility accelerometry
a study to evaluate the product feasibility of a new silicone hydrogel contact lens

Conditions: Myopia

Summary: the objective of this study is to determine the clinical feasibility and to evaluate the product performance of investigational contact lenses developed by bausch + lomb.


Eligibility criteria:
inclusion criteria: * have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings (greater than grade 1 and/or presence of infiltrates). * be adapted wearers of soft contact lenses, wear a lens in each eye, and each lens must be of the same manufacture and brand. * be correctable through spherocylindrical refraction to 32 letters (0.3 logmar) or better (distance, high contrast) in each eye. * be myopic and require lens correction from -0.50 to -6.00 diopters (d) in each eye. exclusion criteria: * an active ocular disease, any corneal infiltrative response or are using any ocular medications. * have worn gas permeable (gp) contact lenses within last 30 days or pmma lenses within last 3 months. * any grade 2 or greater finding during the slit lamp examination that, in the investigator's judgment, interferes with contact lens wear. * any scar or neovascularization within the central 4mm of the cornea. * have had any corneal surgery. * any "present" finding during the slit lamp examination that, in the investigator's judgment, interferes with contact lens wear. * any systemic disease affecting ocular health. * using any systemic or topical medications that will affect ocular physiology or lens performance. * currently wear monovision, multifocal, or toric contact lenses. * allergic to any component in the study care products.
retrospective observational trial on reasons for withdraw of adjuvant tamoxifen in breast cancer patients

Conditions: Breast Cancer

Summary: retrospective observational trial on reasons for withdraw of adjuvant tamoxifen in breast cancer patients


Eligibility criteria:
inclusion criteria: * breast ca patients with surgery and withdraw of adjuvant treatment with tamoxifen for tam related aes * documented reasons for treatment withdrawal exclusion criteria: * enrollment in other studies * treatment withdraw for other causes than tam related aes

Keywords: breast cancer adjuvant tam post-menopausal women
turkish version of the measure of processes of care (mpoc)

Conditions: Cerebral Palsy; Muscular Dystrophies; Autism Spectrum Disorder; Traumatic Brain Injury; Down Syndrome; Disability, Developmental; Disability Physical

Summary: family-centred care (fcs) is considered the best practice in providing rehabilitation to children with disabilities and special needs. family-centred care has been described as a partnership approach to healthcare decision making. as a philosophy of healthcare, today many multidisciplinary healthcare facilities have organized their services according to a family-centred approach. themeasure of processes of care (mpoc) is the most widely used instrument to assess parents' self-reported experiences of family-centred behaviours of rehabilitation services providers. the aim of this study is to translate the scale to turkish and to determine validity and reliability of the measure of processes of care (mpoc 56- 20- sp)

the mpoc is a questionnaire designed to find out what parents of children with disabilities think of the services they and their children receive and how these services affect their psychosocial outcome. mpoc exists in two versions: the 56-item version was published in 1995 and the mpoc-20 in 2004. the20-item version was developed due to disadvantage of the longer version, because its completion can be very time consuming and the consequences of low respondent percentages . king and colleagues assert that the56-item mpoc is useful for research, while the mpoc-20 is better applied as a measure of parents' perceptions of the elements of fcs. the 20 items in the short version are distributed among the same ﬁve scales as in the mpoc-56. this ensures that the mpoc-56/20 captures aspects of care and services that have most importance for parents. the items are included in one of the following ﬁve scales: 1 enabling and partnership; 2 providing general information; 3 providing speciﬁc information about the child; 4 coordinated and comprehensive care; 5 respectful and supportive care. the measure of processes of care for service providers (mpoc-sp) was developed to assess fcs from the perspective of professionals. the mpoc-sp has also been used in many different studies with different populations.

Eligibility criteria:
inclusion criteria: * to be diagnosed as disabilities and special needs * pediatric service providers who agree to participate to study exclusion criteria: * children whose family didn't accept to participate to study

Keywords: mpoc validity and reliability